CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|August 1, 2009
FDA Pipeline preview, August 2009 (trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, velaglucerase alfa)
Recent FDA action (through August 2009) related to trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, and velaglucerase alfa
Advertisement
Complete response
Recommended for approval
Not recommended for approval
Priority review
Orphan drug designation
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Blood RNA risk score from 31 small RNAs flags Lung Cancer in smokers up to 10 years early, potentially guiding earlier LDCT screening.
The CEO and founder of a digital behavior company has advice for health plans considering asynchronous behavioral health services like those that his company provides.
In this interview, Melody Chang, RPh, BCOP, MBA, vice president of pharmacy operation at the American Oncology Network, discusses the network's pharmacy strategy and priorities.
The purchase comes as the "big 3" drug wholesalers are coming under scrutiny for their market dominance and the possible perils of vertical integration.
High prices and cutbacks in ACA and Medicaid coverage leave many patients unable to medical bills.
In this discussion, Heather Burrell-Ward, M.D., provides an overview of her recent study that found TMS aimed at the default mode network improved processing speed in schizophrenia.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
McKesson, private equity firm buy home infusion company, Option Care Health
2
Medicare Advantage needs fixing. Here are 3 feasible repairs
3
Medical debt burdens more than 1 in 4 adults in the U.S., survey finds
4
Blood RNA panel linked to lung cancer risk up to 10 years before diagnosis
5